Pathogen-Based Therapy — Bacteria Adapted from Lancet. 2010;375(9717):846-55. [ 1] and Clin Microbiol Rev. 2002;15(4):527-44. [ 2]
▸ Click on the following categories to expand treatment regimens.
▸ Proteus vulgaris, Proteus rettgeri
▸ Staphylococcus epidermidis
▸ Streptococcus agalactiae
▸ Mycobacterium tuberculosis
Brucella melitensis
Preferred Regimen
▸ Doxycycline 100 mg PO bid for ≥6 weeks
PLUS
▸ Streptomycin 15 mg/kg IM qd for 2–3 weeks OR ▸ Rifampin 600–900 mg qd for ≥6 weeks
Alternative Regimen
▸ Doxycycline 100 mg PO bid for ≥6 weeks
PLUS
▸ Gentamicin 5 mg/kg IV qd for 7 days
Adapted from PLoS Med. 2007;4(12):e317. [ 3] and Lancet Infect Dis. 2007;7(12):775-86. [ 4] and Cochrane Database Syst Rev. 2012;10:CD007179. [ 5]
Methicillin-Sensitive S. aureus
Preferred Regimen
▸ Nafcillin 2 g IV q6h OR ▸ Clindamycin 900 mg IV q8h
Alternative Regimen
▸ Cefazolin 0.25–1 g IV/IM q6–8h OR ▸ Vancomycin 500 mg IV q6h (or 1 g IV q12h)
Methicillin-Resistant S. aureus (Adult)
Preferred Regimen
▸ Vancomycin 15–20 mg/kg IV q8–12h OR ▸ Daptomycin 6 mg/kg IV q24h OR ▸ Linezolid 600 mg PO/IV q12h
Alternative Regimen 1
▸ TMP-SMX 3.5–4.0 mg/kg PO/IV q8–12h (TMP component)
PLUS
▸ Rifampin 300–600 mg PO/IV q12h
Alternative Regimen 2
▸ Clindamycin 600 mg IV/IM q8h
Methicillin-Resistant S. aureus (Pediatric)
Preferred Regimen
▸ Vancomycin 15 mg/kg IV q6h OR ▸ Clindamycin 10 mg/kg PO/IV q6h (or 13 mg/kg PO/IV q8h)
Alternative Regimen
▸ Daptomycin 6–10 mg/kg IV q24h OR ▸ Linezolid 10 mg/kg PO/IV q8h (Maximum: 600 mg/dose)
Adapted from Clin Infect Dis. 2011;52(3):e18-55. [ 6]
Methicillin-Sensitive S. epidermidis
Preferred Regimen
▸ Nafcillin 2 g IV q6h OR ▸ Clindamycin 900 mg IV/IM q8h
Alternative Regimen
▸ Cefazolin 0.25–1 g IV/IM q6–8h OR ▸ Vancomycin 500 mg IV q6h (or 1 g IV q12h)
Methicillin-Resistant S. epidermidis
Preferred Regimen
▸ Vancomycin 500 mg IV q6h (or 1 g IV q12h) OR ▸ Linezolid 600 mg IV q12h
Alternative Regimen 1
▸ TMP-SMX 3.5–4.0 mg/kg PO/IV q8–12h (TMP component) OR ▸ Minocycline 200 mg PO x 1 dose, then 100 mg PO q12h
PLUS
▸ Rifampin 300–600 mg PO/IV q12h
Alternative Regimen 2
▸ Clindamycin 900 mg IV/IM q8h
Mycobacterium tuberculosis
Intensive Phase
▸ Isoniazid 5mg/kg PO q24h for 2 months OR ▸ Isoniazid 10 mg/kg PO 3 times per week × 2 months
PLUS
▸ Rifampicin 10 mg/kg PO q24h for 2 months OR ▸ Rifampicin 10 mg/kg PO 3 times per week × 2 months
PLUS
▸ Pyrazinamide 25mg/kg PO q24h for 2 months OR ▸ Pyrazinamide 35 mg/kg PO 3 times per week × 2 months
PLUS
▸ Ethambutol 15mg/kg PO q24h for 2 months
Continuation Phase
▸ Isoniazid 5mg/kg PO for 4-7 months OR ▸ Isoniazid 10 mg/kg PO 3 times per week × 4-7 months
PLUS
▸ Rifampicin 10 mg/kg PO q24h for 4-7 months OR ▸ Rifampicin 10 mg/kg PO 3 times per week for 4-7 months
Adapted from Treatment of Tuberculosis: Guidelines. [ 7]
Borrelia burgdorferi
Preferred Regimen
▸ Amoxicillin 500 mg q8h for 28 days OR ▸ Doxycycline 100 mg q12h for 28 days OR ▸ Cefuroxime 500 mg q12h for 28 days
Alternative Regimen
▸ Azithromycin 500 mg PO q24h for 7–10 days OR ▸ Clarithromycin 500 mg PO q12h for 14–21 days OR ▸ Erythromycin 500 mg PO q6h for 14–21 days
Adapted from IDSA Guidelines: The Clinical Assessment, Treatment, and Prevention of Lyme Disease, Human Granulocytic Anaplasmosis, and Babesiosis: [ 8]
Treponema pallidum
Preferred Regimen
▸ Penicillin G 2.4 MU IM single dose
Alternative Regimen
▸ Doxycycline 100 mg PO q12h x 14 days OR ▸ Tetracycline 500 mg PO q6h x 14 days OR ▸ Ceftriaxone 1 g IM/IV q24h x 10 -14 days
Adapted from MMWR Recomm Rep. 2006;55(RR-11):1-94[ 9]
Proteus mirabilis
Preferred Regimen
▸ Ampicillin 2 g IV q6h OR ▸ Levofloxacin 500 mg IV/PO q24h
Alternative Regimen
▸ Cefazolin 0.25–1 g IV/IM q6–8h OR ▸ TMP-SMX 8–10 mg/kg/day IV/PO q6–12h (TMP component) OR ▸ Gentamicin 3–5 mg/kg/day IV q6–8h
References
↑ Mathews CJ, Weston VC, Jones A, Field M, Coakley G (2010). "Bacterial septic arthritis in adults" . Lancet . 375 (9717): 846–55. doi :10.1016/S0140-6736(09)61595-6 . PMID 20206778 .
↑ Shirtliff ME, Mader JT (2002). "Acute septic arthritis" . Clin Microbiol Rev . 15 (4): 527–44. PMC 126863 . PMID 12364368 .
↑ Ariza, Javier; Bosilkovski, Mile; Cascio, Antonio; Colmenero, Juan D.; Corbel, Michael J.; Falagas, Matthew E.; Memish, Ziad A.; Roushan, Mohammad Reza Hasanjani; Rubinstein, Ethan; Sipsas, Nikolaos V.; Solera, Javier; Young, Edward J.; Pappas, Georgios (2007). "Perspectives for the Treatment of Brucellosis in the 21st Century: The Ioannina Recommendations". PLoS Medicine . 4 (12): e317. doi :10.1371/journal.pmed.0040317 . ISSN 1549-1277 .
↑ Franco MP, Mulder M, Gilman RH, Smits HL (2007). "Human brucellosis" . Lancet Infect Dis . 7 (12): 775–86. doi :10.1016/S1473-3099(07)70286-4 . PMID 18045560 .
↑ Yousefi-Nooraie R, Mortaz-Hejri S, Mehrani M, Sadeghipour P (2012). "Antibiotics for treating human brucellosis" . Cochrane Database Syst Rev . 10 : CD007179. doi :10.1002/14651858.CD007179.pub2 . PMID 23076931 .
↑ Liu, C.; Bayer, A.; Cosgrove, S. E.; Daum, R. S.; Fridkin, S. K.; Gorwitz, R. J.; Kaplan, S. L.; Karchmer, A. W.; Levine, D. P.; Murray, B. E.; Rybak, M. J.; Talan, D. A.; Chambers, H. F. (2011). "Clinical Practice Guidelines by the Infectious Diseases Society of America for the Treatment of Methicillin-Resistant Staphylococcus aureus Infections in Adults and Children". Clinical Infectious Diseases . 52 (3): e18–e55. doi :10.1093/cid/ciq146 . ISSN 1058-4838 .
↑ Treatment of tuberculosis : guidelin . Geneva: World Health Organization. 2010. ISBN 978-92-4-154783-3 .
↑ . doi :10.1086/522848 .
↑ "http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5511a1.htm" . Retrieved 19 May 2014 .
↑ Fenollar, Florence; Puéchal, Xavier; Raoult, Didier (2007). "Whipple's Disease". New England Journal of Medicine . 356 (1): 55–66. doi :10.1056/NEJMra062477 . ISSN 0028-4793 .